


PERSONAL INFORMATION **Fabio Piscaglia**


 Division of Internal Medicine, via Albertoni 15, 40138 Bologna

**fabio.piscaglia@unibo.it**

 Scopus Author's ID: 7004216443, ORCID <https://orcid.org/0000-0001-8264-1845>

Sex M | Italian

**Current Position:**

- Full Professor of Internal Medicine (SSD MED/09), University of Bologna
- Director of the Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria S.Orsola-Malpighi di Bologna

**Scientific Profile:**

**RESEARCH TOPICS**

Research activities were devoted since the early years (approx. 1995-1997) to the field of liver diseases, with focuses on different aspects initially starting with general hepatology, liver transplantation, portal hypertension and ultrasound applications in upper abdomen. Later on, from around the year 2002 the research interest was more focused on **primary liver tumors** (particularly Hepatocellular Carcinoma), which since then had become one of the main fields of interest and in which scientific achievements were the greatest. These included the Coordination of the Multidisciplinary Italian Guidelines on the Management of Hepatocellular Carcinoma (released online in 2016:

<https://www.webaisf.org/en/2019/08/05/italian-multisocietary-recommendations/>);

GOLDEN PARAGRAPH

the participation to the writing committee (6 members) of the HCC guidelines of the European Association for the Study of the Liver (EASL, J Hepatol 2018;69:182-236, IF 25.0, which attracted 7453 citations so far) and the participation -as the only European member- to the steering committee of the phase 3 trial of Lenvatinib in HCC, published in 2018 (Lancet, 2018;391:1173-1183, IF 79.3, 1877 citations).

Fabio Piscaglia was invited speaker at >10 EASL (European Association for the Study of the Liver) congresses or single topic conferences from 2005.

Many other invitations as speaker. More than 100 continuing invitations at international level (e.g. invited speaker at the 2023 APPLE (Asia Pacific Primary Liver cancer Expert) meeting planned in Seoul, South Korea in July 2023

Principal investigator or sub-investigator in >10 phase I - III trials for systemic pharmacological treatment of HCC (ongoing). This includes trials in the pharmacological treatment of Hepatocellular Carcinoma, as well as an ongoing trial for the treatment of Non Alcoholic Steatohepatitis with micro interfering RNA.

Initial publications were instead addressed to the field of general hepatology and portal hypertension, such as the in the following fields of hepatology.:

- *Progression of liver disease* (exemplary publication: **Piscaglia F**, Gaiani S, Gramantieri L, Zironi G, Siringo S, Bolondi L. Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. *Am J Gastroenterol.* 1998;93:1925-30. **IF 10.8**)
- *Pathogenic mechanisms of complications of portal hypertension* (**Piscaglia F**, Siringo S, et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. *Hepatology.* 2000;31:349-57 **IF 17.4**)
- *Liver Transplantation* (exemplary publication: **Piscaglia F**, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. *Hepatology.* 1999;30:58-64 **IF 17.4**)

From 1997 Basic research with molecular biology techniques also became a field of active personal research. For instance, a relevant topic carried out in the Laboratory of the Uniklinikum of Goettingen in Germany was the identification of Fibulin-2 as a specific marker of liver myofibroblasts compared with hepatic stellate cells (*Gastroenterology*, 1999;117:1205-21. **IF 22.6**)

#### **CLINICAL ACTIVITIES RELATED TO SCIENTIFIC RESEARCH**

- 2020 to current: **Full Professor** of Internal Medicine, at the University of Bologna
- 2018 to current: **Director** of the Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy
- 2005 to current: **Responsible of the outpatient clinic for Liver Tumors** at the Division of Internal Medicine, University of Bologna. For these activities he was appointed a clinical position of high specialization from 2011 entitled "Clinical and Experimental management of primary liver tumors" at the S.Orsola-Malpighi general and university hospital in Bologna.
- 2006 to current: **Secretary of the bimonthly Liver Oncology Meeting** of the S.Orsola-Malpighi hospital, where cases of Hepatocellular Carcinoma are discussed within a multidisciplinary team.
- **Peer reviewer** of submitted abstracts on liver cancer for the annual congresses of the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA), the Italian Association for the study of the liver (AISF) in the last 3 consecutive years.
- Personal performance as first operator of hundreds of ultrasound-guided percutaneous interventions for liver disease (liver biopsies; thermal ablations or percutaneous ethanol injections for liver tumors), acting as referral center on a regional and national basis for HCC.
- Among the first worldwide clinical researcher in Contrast Enhanced Ultrasound and liver Elastography, with personal performance of >2000 examinations. This led to the participation of various guidelines on the clinical use of CEUS and coordination of one of the most cited (Piscaglia F et al, *Ultraschall in der Medizin* 2012;33:33-59, IF 6.6, 860 citations) and coordination of the first ones about Ultrasound Elastography (Bamber J ,....., Piscaglia F. *Ultraschall in der Medizin* 2013;34:169-184, IF 6.6, 791 citations).

Winner as Italian Principal Investigator of significant international competitive grants (such as the one from the European Community and one American National Institute of Health) for studies in the field of liver disease.

#### **Bibliometric Indicators (according to SCOPUS) Up to 2023:**

Scopus Author ID:7004216443

Publications: 462

Citations: 37329

**H index: 81**

H index excluded self-citations: 76

Included within the **115 best Top Italian Scientists in Clinical Medicine**[https://www.topitalianscientists.org/TIS\\_HTML/Top\\_Italian\\_Scientists\\_Clinical\\_Sciences.htm](https://www.topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Clinical_Sciences.htm),which an **H-index of 99 according to Google Scholar**.**3 most relevant publications or patents:**

1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, **Piscaglia F**, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018;391:1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850. **IF 202.7** (5084 citations)

2. **Piscaglia F**, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. *Hepatology*. 2016;63:827-38. doi: 10.1002/hep.28368. **IF 17.4** (628 citations)

3. Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassinetti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, **Piscaglia F\***. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. *J Clin Oncol*. 2022 Dec 13;JCO2200972. doi: 10.1200/JCO.22.00972. **IF 50.1**. **\*senior autor**

**WORK EXPERIENCE**

12.2020 – current

Academic sector. Full Professor of Internal Medicine, at the University of Bologna

31.12.2018 – current

Health Sector. Director of the Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease. Employer: IRCCS Azienda Ospedaliero-Universitaria S.Orsola-Malpighi di Bologna.

1.7.2011 – 30.12.20218

Health Sector. Clinical position of high specialization entitled “Clinical and Experimental management of primary liver tumors” at the S.Orsola-Malpighi general and university hospital in Bologna.

12.2001 – 3.2003 and 3.2005-12.2018

Clinical Activities as Senior Physician (Dirigente Medico di I livello) at the S.Orsola-Malpighi general and university hospital in Bologna

9.2014 – 12.2020

Academic Sector. Associate Professor of Internal Medicine, Employer: University of Bologna

3.2005 – 9.2014

Academic Sector. Assistant Professor in Internal Medicine, University of Bologna

EDUCATION AND TRAINING

---

- 1979  
Course in Commercial Typewriting. Awarded the Diploma of Typewriter.
- 1978-1983  
Courses in English in Rimini. Award: "First Certificate in English" of the Cambridge School of English, grade B
- 1981-1986  
High School Course at the Liceo Classico Giulio Cesare, Rimini.  
Final marks 56/60. Foreign language at School: German.
- 1986 – 1992  
School of Medicine at the University of Bologna. Awarded the title of M.D.  
During the University studies pass of a total of 34 exams, all of which with the top mark of 30/30 and 29 of 34 also "cum laude"
- 1993 - 1998  
Course of Specialization in Internal Medicine, University of Bologna. Awarded the title of Specialist.
- 1998-2002  
PhD Program in Ultrasound in Human and Veterinary Medicine, University of Bologna
- 1992  
Pass of the exam for the Italian Medical License (Awarded the "Italian Abilitazione Medica")
- 1997  
Pass of the entire United States Medical License Exam (Awarded the US-MLE)

## PERSONAL SKILLS

## Organisational / managerial skills

- Sport Leadership: Appointed Captain of the Regional (Emilia-Romagna) team of the best basketball players of his age in 1982). Nickname as player: “Chief”.
- Organizational skills: 1) Secretary of the Local Organization Committee of the World Congress of Ultrasound (WFUMB Congress held in Florence in May 2000); 2) General Secretary of Euroson Congress 2006, European Congress of Ultrasound held in Bologna, Italy in 2006); 2013 President of the Euroson Congress held in Stuttgart, Germany.
- Clinical Leadership (currently responsible for a team of 12 senior doctors and more than 20 residents, providing recognized optimal health care and high volume of scientific publications (more than 60 by this team in PubMed only in 2021). Appointed director of the first temporary Unit of Internal Medicine abruptly set up to host only COVID+ patients in the first pandemic wave in Spring 2020.
- Scientific Organizational Leadership: Research Team Leader. Principal Investigator of several (over 10) Phase 3 trial for drugs in liver diseases. The high standard of the coordination of such activities is remarked by the very successful pass of a planned inspection of the research unit chaired by F. Piscaglia, carried out by the Italian Drug National Agency (Agenzia Italiana del Farmaco, AIFA) in 2021
- Academic Organization Skills: 3.2017 – current. Director of the PhD Program in General and Service Medical Sciences, University of Bologna. Coordinator of the fundings of the bursaries and grants and agreements for external support. 1.2022-current. Director of the School of Specialization in Internal Medicine, University of Bologna
- UEMS Board Certified Transplant Hepatologist

## ADDITIONAL INFORMATION

## Most 10 relevant publications in the last 10 Years

1. D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. *J Hepatol.* 2022;76:1185-1198. doi: 10.1016/j.jhep.2021.11.013. **IF 30.0**
2. Taru MG, Leucuta DC, Lupsor-Platon M, Turco L, Ferri S, Hashim A, Orasan OH, Procopet B, Stefanescu H, Morelli MC, **Piscaglia F**, Ravaoli F. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multi-level random effects model meta-analysis. *Hepatology.* 2024 Dec 16. doi: 10.1097/HEP.0000000000001190. Epub ahead of print. PMID: 39689354. **IF=12.9**
3. Turco L, Taru MG, Vitale G, Stefanescu H, Mirici Cappa F, Berardi S, Baldan A, Di Donato R, Pianta P, Vero V, Vizioli L, Procopciuc LM, Procopet B, Morelli MC, **Piscaglia F**. Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment. *Clin Gastroenterol Hepatol.* 2024 Aug 30:S1542-3565(24)00780-8. doi: 10.1016/j.cgh.2024.08.012. Epub ahead of print. PMID: 39209198. **IF=11.6**
4. Tovoli F, Dadduzio V, De Lorenzo S, ..., **Piscaglia F**. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. *Liver Cancer.* 2021;10:370-379. doi: 10.1159/000515551. **IF 11.1.**
5. Tovoli F, Guerra P, Iavarone M, ..., **Piscaglia F**. Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic

- Cholangiocarcinoma Arisen in Liver Cirrhosis. *Liver Cancer*. 2020;9:744-755. doi: 10.1159/000509059. **IF 11.1**
6. Tovoli F, Ielasi L, Casadei-Gardini A, ..., **Piscaglia F**. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. *J Hepatol*. 2019;71:1175-1183. doi: 10.1016/j.jhep.2019.08.015. **IF 30.0**
  7. Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassinetti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, **Piscaglia F\***. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. *J Clin Oncol*. 2022 Dec 13:JCO2200972. doi: 10.1200/JCO.22.00972. **IF 50.1**.
  8. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, **Piscaglia F**, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*. 2018;391:1163-1173. doi: 10.1016/S0140-6736(18)30207-1. **IF 202.7**
  9. Terzi E, Iavarone M, Pompili M, ..., **Piscaglia F**; LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. *J Hepatol*. 2018;68:485-492. doi: 10.1016/j.jhep.2017.11.007. **IF 30.0**.
  10. **Piscaglia F**, Svegliati-Baroni G, Barchetti A, et al; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. *Hepatology*. 2016;63:827-38. doi: 10.1002/hep.28368. **IF 17.4**

#### Complete List of Published Work in Google Scholar:

<https://scholar.google.it/citations?user=qfLoIPYAAAAJ&hl=it>

List of publications in Google Scholar (producing an H-index of 99 (65 as of 2020) and an i-10 index of 328 (255 as of 2020) <https://scholar.google.es/citations?user=qfLoIPYAAAAJ&hl=en>

#### Complete List of Published Work in Pubmed:

<https://pubmed.ncbi.nlm.nih.gov/?term=piscaglia+f&sort=date>

#### Projects/Grants

2013-2017

European Marie Curies funding project (#612273) in conjunction with a Spanish Academic Center and a Spanish Small Enterprise on the use of Contrast Enhanced Ultrasound in prognostication of patients with portal hypertension. Local 310.000 Euros

2017-2021

National Institute of Health (NIH) of United States of America grant (PI Thomas Jefferson University of Philadelphia, 1R01CA215520-01A1) on Contrast enhanced ultrasound Liver Imaging Reporting Archive Data System (CEUS LI RADS) for the diagnosis of hepatocellular carcinoma. Local 115.000 Euros

2022-2025

PNRR M6/C2\_call 2022". Title: Italian Autoimmune Liver Disease (IT-AILD) Clinical Research Network (2022-2025). Collaborative project including 4 Italian Units. Main goal: To identify the areas of unmet need in AILD, which relate principally to an improvement of the understanding of the basis and the course of the diseases, symptom management, trial design and delivery, and structured care delivery; and propose the development of the AILD Clinical Research Network (IT-AILD-CRN).

**Conferences** Over 100 Oral Communications at international congresses

One of the most relevant: Honorary Lecture entitled to the World Federation of Ultrasound in Medicine and Biology on occasion of the European Congress of Ultrasound Euroson 2015 held in Athens Greece entitled “Point of care ultrasound in liver disease for the modern hepatologist”

**National and International Society  
Positions and Large Events  
Leadership**

- 2008-2011: Member of the Governing Board of the Italian Association for the Study of Liver Disease.
- 2011-2013: President of the European Federation of Societies for Ultrasound in Medicine and Biology (28 Nations, over 20.000 members).
- 2011-present: Member of the Board of Directors of the International Contrast Ultrasound Society (ICUS).
- 2000: General Secretary of the Organizing Committee of the WFUMB (World Federation of Societies for Ultrasound in Medicine and Biology) triennial congress, held in Florence. >2500 attendees.
- 2009: Director of the Euroson School on Contrast Enhanced Ultrasound in Liver, Biliary, Pancreatic and Gastrointestinal Disease, Bologna Sept 16-18 promoted by EASL, European Association for the Study of the Liver.
- 2012: President of EUROSON 2012, the 24th Congress of the European Federation of Societies for Ultrasound in Medicine and Biology Madrid, Spain
- 2013: President of EUROSON 2013, the 25th Congress of the European Federation of Societies for Ultrasound in Medicine and Biology Leipzig, Germany
- 2013: Winner of a Marie Curie, Industry And Academia Cooperation action program from the European Union grant as responsible of one of the 3 centers submitting the application (University of Bologna, University of Barcelona, Yma from Barcelona as Small Industry) for a global budget of 1.4 M Euros.
- 2017: Awardee of a NIH funded grant “R01 CA215520/CA/NCI NIH HHS/United States” (PI. Prof. Andrej Lyschik) as responsible of one of the 11 centers submitting the application and with a strong contributing role to the project leading to the position of last author in the final publication.
- 2024: Leader Member of the organizing committee of EUROSON 2024, the 34th Congress of the European Federation of Societies for Ultrasound in Medicine and Biology Naples, Italy
- 2024-2026 President-Elect, of SIUMB, Società Italiana di Ultrasonologia in Medicina e Biologia (Italian Society of Ultrasound in Medicine and Biology).
- 2025.Feb Member of the Committee for the Scientific Program of the EASL, European Association for the Study of the Liver, Liver Cancer Summit planned in Paris, France.

**Current Editorial Positions**

- 2013-current: Associate Editor of Ultraschall in der Medizin / European Journal of Ultrasound (IF 3.1 as of 2024)
- 2016-2019: Associate Editor of Digestive and Liver Disease (IF 3.0 as of 2020)
- 2012- current: Member of the Editorial Board of “Liver Cancer”. (IF 11.8 as of 2023)
- 2014-current. Member of the Editorial Board of Echo Research and Practice (Official Journal of the British Society of Echocardiography)
- 2023: Member of the Editorial Board of “J Hepatol Reports” (IF 9.1 as of 2023)
- Peer reviewer for several (>25) international scientific journal with an Impact Factor >1

#### Grant Review and Scientific Advisory Boards *(selected)*

- 2012-present: VQR, Italian panel for the review of university national scientific activities (Verifica della Qualità della Ricerca)
- 2012 and 2024: Expert reviewer for grant selection for the “Swiss National Science Foundation (SNSF)
- 2015 – current: Member of REPRISE: Register of Expert Peer Reviewers for Italian Scientific Evaluation
- 2008, 2013: Member of the writing committee and author of the EFSUMB and WFUMB guidelines on the use of Contrast Enhanced Ultrasound for Hepatic Applications.
- 2012: Promoter and first author of the European Guidelines for the use of Contrast Enhanced Ultrasound in non-hepatic applications, whose publication (Piscaglia F, Nolsøe C, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. *Ultraschall Med.* 2012;33:33-59) has been cited already almost 1000 times according to GoogleScholar and has been one of the most influential publications ever in the field.
- 2013: Promoter and member of the steering committee and senior author of the EFSUMB Guidelines and Recommendations on the clinical use of ultrasound Elastography. Part 1, Technology (*Ultraschall Med*, in press April 2013) and Part 2, Clinical (*Ultraschall Med*, in press June 2013) each article cited around 1000 times.
- 1998 – current: Invited to deliver a total of more than 100 lectures at international events, among which:
- 2005 – current: Invited speaker every year at the annual meetings of the European Association for the Study of Liver (EASL). Organizer of Clinical School on Liver Imaging, entirely supported by EASL and held in Bologna in 2012 for young scientists from European Countries.
- 2006-current: invited speaker at every biannual meeting of EFSUMB.
- 2012: first opponent per PhD commission in Gastroenterology at university of Bergen, Norway. PhD Thesis of dr. Havre, entitled: Tissue characterization by ultrasound strain imaging. Methodological aspects and gastroenterological applications.

#### Honours and awards

- From 11.2016: Rectoral nomination as “Visiting Professor” for post-doctoral studies at the Victors Babes University in Cluj-Napoca, Romania
- Awarded the Honorary Membership of the National Society for Ultrasound of Romania (in 2010) and Bulgaria (in 2016).
- 2015: Honorary Lecture entitled to World Federation of Ultrasound in Medicine and Biology on occasion of the European Congress EUROSON 2015, Athens, Greece, entitled “Point of care ultrasound in liver disease for the modern hepatologist”
- 1993: Awarded the prize for the best scholar curriculum during the Medical Course among all graduated students at the University of Bologna Academic in the academic year 1992-1993



## Appendix

## Appendix 1 – Scientific publications in the last year (2024, Up to January 2025)

***According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV***

*Bologna, 21<sup>st</sup> of January 2025*

## Appendix 1 – Scientific publications in the last year (2024, Up to January 2025)

1. Giannini EG, Pasta A, Plaz Torres MC, Pieri G, Cabibbo G, Sangiovanni A, **Piscaglia F**, Campani C, Missale G, Vidili G, Ghittoni G. Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma. *Liver International*. 2025 Feb;45(2):e16185.
2. Cillo U, Caregari S, Barabino M, Billato I, Marchini A, Furlanetto A, Lazzari S, Brolese M, Ballo M, Biasini E, Celsa C, **Piscaglia F** et al. Hierarchically positioning laparoscopic microwave ablation in the therapeutic span of early hepatocellular carcinoma: a real-life comparative analysis. *Annals of Surgical Oncology*. 2025 Feb;32(2):1063-72.
3. Kuon Yeng Escalante CM, Siu Xiao T, Kono Y, **Piscaglia F**, Wilson SR, Medellin A, Rodgers SK, Planz V, Kamaya A, Fetzer DT, Berzigotti A. Inter-Reader Agreement for Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System Major Features and Final Categorization: A Subanalysis From a Prospective Multicenter Study. *Journal of Ultrasound in Medicine*. 2025 Feb;44(2):349-57.
4. Montagner A, Arleo A, Suzzi F, D'Assoro AB, **Piscaglia F**, Gramantieri L, Giovannini C. Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies. *Biomolecules*. 2024 Dec 11;14(12):1581.
5. Tovoli F, Pallotta DP, Vivaldi C, Campani C, Federico P, Palloni A, Dalbeni A, Soldà C, Lani L, Svegliati-Baroni G, Garajova I... **Piscaglia F**. Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma. *Digestive and Liver Disease*. 2024 Dec 1;56(12):2079-84.
6. Arleo A, Montagner A, Giovannini C, Suzzi F, **Piscaglia F**, Gramantieri L. Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC. *Biomolecules*. 2024 Nov 24;14(12):1496.
7. Boccata A, D'Ardes D, Moronti V, Santilli J, Cipollone A, Lessiani G, Di Gregorio N, Serra C, **Piscaglia F**, Ferri C, Cipollone F. From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status. *Medicina*. 2024 Oct 31;60(11):1781.
8. Stefanini B, Marseglia M, Penazza S, **Piscaglia F**. Teamwork makes the dream work?—dissecting the role of triple therapy: radiotherapy combined with sintilimab plus bevacizumab for hepatocellular carcinoma and malignant portal vein invasion. *AME Clinical Trials Review*. 2024 Oct 25;2.
9. Siu Xiao T, Kuon Yeng Escalante CM, Tahmasebi A, Kono Y, **Piscaglia F**, Wilson SR, Medellin-Kowalewski A, Rodgers SK, Planz V, Kamaya A, Fetzer DT. Combining CEUS and CT/MRI LI-RADS major imaging features: diagnostic accuracy for classification of indeterminate liver observations in patients at risk for HCC. *Abdominal Radiology*. 2024 Oct 23:1-2.
10. Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G... **Piscaglia F**... Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study. *Liver Cancer*. 2024 Oct 10;13(5):522-36.
11. Boccata A, **Piscaglia F**, Serra C. Acute Abdomen in the Modern Era. *The New England journal of medicine*. 2024 Oct 3;391(13):1262.
12. Stefanini B, Manfredi GF, D'Alessio A, Fulgenzi CA, Awosika N, Celsa C, Pirisi M, Rigamonti C, Burlone M, Vincenzi F, Minisini R.. **Piscaglia F** .... Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma. *Expert Review of Gastroenterology & Hepatology*. 2024 Oct 2;18(10):647-60.
13. Taru MG, Leucuta DC, Lupsor-Platon M, Turco L, Ferri S, Hashim A, Orasan OH, Procopet B, Stefanescu H, Morelli MC, **Piscaglia F**, Ravaioli F. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multi-level random effects model meta-analysis. *Hepatology*.:10-97.
14. Zavatta G, Vitale G, Morelli MC, Pianta P, Turco L, Cappa FM, Ravaioli M, Cescon M, **Piscaglia F**, Altieri P, Pagotto U. High bone fracture risk in a large modern cohort of liver transplant recipients. *Internal and Emergency Medicine*. 2024 Sep 27:1-2.

15. Bocatonda A, D'Ardes D, Tallarico V, Guagnano MT, Cipollone F, Schiavone C, **Piscaglia F**, Serra C. Role of Lung Ultrasound in the Detection of Lung Sequelae in Post-COVID-19 Patients: A Systematic Review and Meta-Analysis. *Journal of Clinical Medicine*. 2024 Sep 21;13(18):5607.
16. Bocatonda A, **Piscaglia F**. Predictive role of microvesicles in cirrhotic patients: A promised land or a land of confusion? A narrative review. *Annals of Hepatology*. 2024 Sep 11:101563.
17. Stefanini B, Mandrioli D, Vornoli A, Salomone A, Sgargi D, Manservigi F, **Piscaglia F**, Tovoli F. Occupational exposure and risk of complications in MASLD patients: updates from a case: control study. *Digestive and Liver Disease*. 2024 Sep 1;56:S321.
18. Sansone V, Auteri G, Tovoli F, Mazzoni C, Paglia S, Di Pietro C, Vianelli N, Cavo M, Palandri F, **Piscaglia F**. Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis. *Journal of Ultrasound*. 2024 Sep;27(3):715-22.
19. Turco L, Taru MG, Vitale G, Stefanescu H, Cappa FM, Berardi S, Baldan A, Di Donato R, Pianta P, Vero V, Vizioli L.. **Piscaglia F**. Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment. *Clinical Gastroenterology and Hepatology*. 2024 Aug 30.
20. Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F, Zavatta G, **Piscaglia F**, Petroni M, Ravaioli F. (2024). RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. *International Journal of Molecular Sciences*, 25(17), 9193.
21. D'Abundo L, Bassi C, Callegari E, Moshiri F, Guerriero P, Michilli A, Mora F, Gardini AC, Sangiovanni A, **Piscaglia F**, Sabbioni S. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy. *Scientific Reports*. 2024 Aug 9;14(1):18551.
22. Caputo F, Casabianca A, Brazzale C, Lungaro L, Costanzini A, Caio G, De Giorgio R, Testino G, **Piscaglia F**, Caraceni P. Use of sodium oxybate for the treatment of alcohol withdrawal syndrome in patients with acute alcohol-associated hepatitis: A 4-patient case report. *Medicine*. 2024 Aug 2;103(31):e39162.
23. Stefanini B, Ielasi L, Casadei-Gardini A, Piscopo M, Tortora R, Lani L, Pressiani T, Sansone V, Sacco R, Magini G, Renzulli M.. **Piscaglia F** ... Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib. *Gastroenterology Insights*. 2024 Jun 22;15(3):519-29.
24. Boe M, Vicari S, Bocatonda A, **Piscaglia F**. The importance of ultrasound-guided biopsy: lesson from a case of liver metastasis from uveal melanoma. *Journal of Ultrasound*. 2024 Jun 12:1-8.
25. Kono Y, **Piscaglia F**, Wilson SR, Medellin A, Rodgers SK, Planz V, Kamaya A, Fetzer DT, Berzigotti A, Sidhu PS, Wessner CE. Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC. *Abdominal Radiology*. 2024 Jun 11:1-1.
26. Evans TJ, Kudo M, Cheng AL, Wyrwicz LS, Ngan RK, Blanc JF, Baron AD, Vogel A, Ikeda M, **Piscaglia F**, Qin S. ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.
27. Bocatonda A, Baldini C, Rampoldi D, Romani G, Corvino A, Cocco G, D'Ardes D, Catalano O, Vetrugno L, Schiavone C, **Piscaglia F**. Ultrasound-Assisted and Ultrasound-Guided Thoracentesis: An Educational Review. *Diagnostics*. 2024 May 29;14(11):1124.
28. Lyshchik A, Fetzer DT, Kono Y, Wilson SR, Dietrich CF, Clevert DA, Meloni MF, Jang HJ, Kim TK, Lee JM, Minami Y... **Piscaglia F**. Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024. *Radiology*. 2024 May 28;311(2):e232369.
29. Vitale A, Romano P, Cillo U, Busti M, Nezi G, De Carlis R, Ratti F, Milana F, Donadon M, Marinelli L, Razionale F...**Piscaglia F**... Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma. *JAMA surgery*. 2024 May 15.
30. Scheiner B, D'Alessio A, Kim G, Goldin RD, Fulgenzi CA, Balcar L, Pomej K, Cheon J, Krall A, Hucke F, Di Tommaso L..**Piscaglia F**.... Machine learning-based assessment of tumour-infiltrating lymphocytes predicts outcomes in patients with hepatocellular carcinoma undergoing atezolizumab and bevacizumab treatment. *Zeitschrift für Gastroenterologie*. 2024 May;62(05):V2.

31. Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V. **Piscaglia F**. Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab. *Liver International*. 2024 May;44(5):1108-25.
32. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY... **Piscaglia F** ...Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. *Targeted Oncology*. 2024 Apr 30:1-5.
33. Boccatonda A, Balletta M, D'Ardes D, Cocco G, **Piscaglia F**, Serra C, Vicari S, Schiavone C. Ultrasound diagnosis of a pseudoaneurysm of the internal right mammary artery. *Journal of Ultrasound*. 2024 Apr 17:1-4.
34. Boccatonda A, Guagnano MT, D'Ardes D, Cipollone F, Vetrugno L, Schiavone C, **Piscaglia F**, Serra C. The Role of Contrast-Enhanced Ultrasound in the Differential Diagnosis of Malignant and Benign Subpleural Lung Lesions. *Journal of Clinical Medicine*. 2024 Apr 16;13(8):2302.
35. **Piscaglia F**, Ikeda K, Cheng AL, Kudo M, Ikeda M, Breder V, Ryoo BY, Mody K, Ren M, Ramji Z, Sung MW. Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study. *Cancer*. 2024 Apr 15;130(8):1281-91.
36. Boccatonda A, Del Cane L, Marola L, D'Ardes D, Lessiani G, Di Gregorio N, Ferri C, Cipollone F, Serra C, Santilli F, **Piscaglia F**. Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review. *Life*. 2024 Apr 4;14(4):473.
37. Tovoli F, Stefanini B, Mandrioli D, Mattioli S, Vornoli A, Sgargi D, Manservigi F, **Piscaglia F**, Curti S, Bolondi L. Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study. *Digestive and Liver Disease*. 2024 Apr 1;56(4):571-8.
38. Kondili LA, Zanetto A, Quaranta MG, Ferrigno L, Panetta V, Calvaruso V, Zignego AL, Brunetto MR, Raimondo G, Biliotti E, Ieluzzi D... **Piscaglia F**.... Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort. *United European Gastroenterology Journal*. 2024 Apr;12(3):352-63.
39. Stefanini B, Tovoli F, Trevisani F, Marseglia M, Di Costanzo GG, Cabibbo G, Sacco R, Pellizzaro F, Pressiani T, Chen R, Ponziani FR... **Piscaglia F**. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib. *Internal and Emergency Medicine*. 2024 Mar 29:1-0.
40. Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G... **Piscaglia F** ....  $\alpha$ -FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. *International Journal of Cancer*. 2024 Mar 15;154(6):1043-56.
41. Stefanini B, Ielasi L, Pallotta DP, Penazza S, Marseglia M, **Piscaglia F**. Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?. *Journal of Liver Cancer*. 2024 Mar 12;24(1):23-32.
42. Biselli M, Reggidori N, Iavarone M, Renzulli M, Lani L, Granito A, **Piscaglia F**, Lorenzini S, Alimenti E, Vara G, Caraceni P. Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. *Cancers*. 2024 Mar 7;16(6):1080.
43. Boccatonda A, Gentilini S, Zanata E, Simion C, Serra C, Simioni P, **Piscaglia F**, Campello E, Ageno W. Portal Vein Thrombosis: State-of-the-Art Review. *Journal of Clinical Medicine*. 2024 Mar 6;13(5):1517.
44. Giannini EG, Pasta A, Pieri G, Plaz Torres MC, Marseglia M, Pelizzaro F, Sangiovanni A, Cabibbo G, Ghittoni G, Di Marco M, Foschi FG... **Piscaglia F** .... Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma. *Liver International*. 2024 Mar 1.
45. Vianello C, Monti E, Leoni I, Galvani G, Giovannini C, **Piscaglia F**, Stefanelli C, Gramantieri L, Fornari F. Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response. *Cancers*. 2024 Feb 13;16(4):766.
46. Boccatonda A, **Piscaglia F**. New perspectives on the use of artificial intelligence in the ultrasound evaluation of lung diseases. *Journal of Ultrasound*. 2024 Feb 5:1-3.
47. Balcar L, Scheiner B, Fulgenzi CA, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L.. **Piscaglia F** .... A meta-analysis and real-world cohort study on the sex-related differences in

- efficacy and safety of immunotherapy for hepatocellular carcinoma. *JHEP reports*. 2024 Feb 1;6(2):100982.
48. Cabibbo G, Daniele B, Borzio M, Casadei-Gardini A, Cillo U, Colli A, Conforti M, Dadduzio V, Dionisi F, Farinati F, Gardini I. **Piscaglia F** .... Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPEC-IAP), Italian Society of Surgery .... *Digestive and Liver Disease*. 2024 Feb 1;56(2):223-34.
  49. Gramantieri L, Suzzi F, Bassi C, D'Abundo L, Tovoli F, Bruccoleri M, Marseglia M, Alimenti E, Fornari F, Negrini M, Iavarone M... **Piscaglia F** ... Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma. *European Journal of Immunology*. 2024 Feb;54(2):2350637.
  50. Dietrich CF, Correas JM, Cui XW, Dong Y, Havre RF, Jenssen C, Jung EM, Krix M, Lim A, Lassau N, **Piscaglia F**. EFSUMB Technical Review–Update 2023: Dynamic Contrast-Enhanced Ultrasound (DCE-CEUS) for the Quantification of Tumor Perfusion. *Ultraschall in der Medizin-European Journal of Ultrasound*. 2023 Sep 25.
  51. Lyschchik A, Wessner CE, Bradigan K, Eisenbrey JR, Forsberg F, Yi M, Keith SW, Kono Y, Wilson SR, Medellin A, Rodgers SK.. **Piscaglia F**. Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe. *Hepatology*. 2024 Feb 1;79(2):380-91.
  52. Santangeli E, Abbati C, Chen R, Di Carlo A, Leoni S, **Piscaglia F**, Ferri S. Pathophysiological-Based Nutritional Interventions in Cirrhotic Patients with Sarcopenic Obesity: A State-of-the-Art Narrative Review. *Nutrients*. 2024 Jan 31;16(3):427.
  53. Ielasi L, Stefanini B, Conti F, Tonnini M, Tortora R, Magini G, Sacco R, Pressiani T, Trevisani F, Foschi FG, **Piscaglia F**. Comparative analysis of subclassification systems in patients with intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Classification B) receiving systemic therapy. *Current Oncology*. 2024 Jan 19;31(1):547-57.
  54. Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY.. **Piscaglia F** ... Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study. *Oncology*. 2024:1-27.
  55. Finn RS, Qin S, **Piscaglia F**, Evans TR, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT.
  56. Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY... **Piscaglia F** .. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma. *Targeted Oncology*. 2024 Jan;19(1):29-39.